Oral Diclofenac in the
Prophylactic Treatment of
Recurrent Renal Colic

Lærum, E; Ommundsen, Ole Eigil; Grønseth, John Eddy; Christiansen, Anne Hjøllund; Fagertun, H.

doi:10.1159/000475031

Cited by 77 publications

(32 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ureteropelvic consequences of the acute attempt to eliminate stones, such as ureteral oedema, increased peristalsis and pelvic pressure, may be effectively alleviated by non steroidal anti-inflammatory drugs through inhibition of prostaglandin synthesis. Hospital readmissions and new pain episodes may be avoided through these drugs, but time until complete elimination or even the likelihood of stone passing appears to be unaffected [70] . During its use, renal function should be monitored due to the risk of nephrotoxicity.…”

Section: Management Of Non-acute Pediatric Ulmentioning

confidence: 99%

Pediatric primary urolithiasis: Symptoms, medical management and prevention strategies

Penido

Tavares

2015

WJN

View full text Add to dashboard Cite

In the past few decades pediatric urolithiasis has become more frequent. The reason for this increase is not completely clear but has been attributed to changes in climate, nutritional habits and possibly other environmental factors. Although less frequent than adult stone disease, urolithiasis in the pediatric age group is also related to significant morbidity, particularly since stones tend to recur, and, thus, should not be underestimated. Most children with idiopathic stone disease have an underlying metabolic abnormality substantiating the importance of metabolic evaluation already following initial diagnosis of urolithiasis. Identification of the metabolic abnormality allows for more specific prescription of non pharmacological and pharmacological interventions aimed at preventing recurrent stone formation. A better understanding of the causes of kidney stone disease will provide better strategies for stone prevention in children.

show abstract

Section: Management Of Non-acute Pediatric Ulmentioning

confidence: 99%

Pediatric primary urolithiasis: Symptoms, medical management and prevention strategies

Penido

Tavares

2015

WJN

View full text Add to dashboard Cite

show abstract

“…All urinary tract stones and ureteric stones in particular, have a significant impact on patients' quality of life. They are a common cause of emergency hospital admission due to severe pain with over 15,000 hospital admissions in England annually (HES data 2006-2007) using over 21,500 bed days, resulting in significant calls on health service resources. The pain leads to a requirement for analgesia, time off work and often repeated hospital admissions for therapeutic interventions.…”

Section: Gp Information Sheet Title Of Projectmentioning

confidence: 99%

“…Such strategies are termed MET. Agents that initially appeared to be useful but then failed to show efficacy in more robustly designed studies included diuretics and administration of high fluid load to increase urinary hydrostatic pressure above the stone; 20 steroidal anti-inflammatory drugs and NSAIDs to reduce ureteric oedema and inflammation around the stone; 21,22 and antimuscarinic drugs to inhibit ureteric muscular contraction. 23 The two drug classes that appear to show efficacy in repeated small-scale RCTs and subsequent meta-analysis are calcium channel antagonists and alpha-adrenoreceptor antagonists.…”

Section: Introductionmentioning

confidence: 99%

Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost-effectiveness analysis of a calcium channel blocker (nifedipine) and an alpha-blocker (tamsulosin) (the SUSPEND trial)

Pickard

Starr

MacLennan

et al. 2015

Health Technol Assess

View full text Add to dashboard Cite

et al. Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost-effectiveness analysis of a calcium channel blocker (nifedipine) and an alpha-blocker (tamsulosin) (the SUSPEND trial). Health Technol Assess 2015;19(63). This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/). Health Technology Assessment is indexed and abstracted inEditorial contact: nihredit@southampton.ac.ukThe full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta This reportThe research reported in this issue of the journal was funded by the HTA programme as project number 08/71/01. The contractual start date was in June 2010. The draft report began editorial review in November 2014 and was accepted for publication in April 2015. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily refle...

show abstract

“…De la misma forma, se han realizado dos estudios que evalú an la eficacia de los AINE en la expulsió n del cá lculo, uno de ellos con celecoxib en dosis de 400 mg 11 y el otro con diclofenaco en dosis de 50 mg 12 . En ninguno de los dos casos se consiguió mejorar la proporció n de cá lculos expulsados.…”

Section: Discusió Nunclassified

“…Inhiben la síntesis de prostaglandinas, relajando el mú sculo liso y disminuyendo la vasodilatació n, y secundariamente la diuresis 15 . En contraposició n con los estudios expuestos previamente 11,12 , en el presente estudio se demostró una mayor proporció n de expulsió n litiá sica en los enfermos tratados con AINE. El mayor tiempo de seguimiento de nuestro estudio puede ser el hecho diferenciador que explique ese hallazgo.…”

Section: Discusió Nunclassified

Factores predictivos para la expulsión de la litiasis ureteral

et al. 2010

View full text Add to dashboard Cite

informació n del artí culo Historia del artículo:Recibido el 14 de febrero de 2010 Aceptado el 13 de mayo de 2010On-line el 18 de junio de 2010Palabras clave: Aná lisis multivariante Litiasis ureteralTratamiento mé dico r e s u m e n El tratamiento mé dico, la litotricia y la ureteroscopia son opciones terapé uticas para el tratamiento de la litiasis ureteral. La ureteroscopia y la litotricia son altamente resolutivas, si bien no está n exentas de riesgos quirú rgicos y anesté sicos. El tratamiento mé dico expulsivo es menos efectivo pero carece de esos riesgos. La selecció n de enfermos para el tratamiento mé dico debe ser cuidadosa, atendiendo a factores como el tamañ o, la composició n y la localizació n de la litiasis.Objetivos: Analizar retrospectivamente el papel de las características litiá sicas y de la medicació n (alfabloqueantes, antiinflamatorios no esteroideos [AINE] o la combinació n de ambos) como factores predictivos de la expulsió n de cá lculos ureterales.Material y métodos: Para el estudio se encontraron disponibles 278 litiasis ureterales correspondientes a 260 enfermos. La variable principal del estudio fue el )resultado clínico* (expulsió n o persistencia de la litiasis). Se analizaron la influencia de la localizació n, el tamañ o, la composició n y la medicació n administrada (alfabloqueantes, AINE o la combinació n de ambos) con el test de la chi cuadrado. A continuació n, se llevó a cabo un aná lisis multivariante con un modelo de regresió n logística para estudiar la influencia de cada una de las variables en presencia del resto de las covariables.Resultados: Se produjo la expulsió n del 34,2% de las litiasis. La localizació n (uré ter pelviano, odds ratio [OR] ¼ 1,823; p ¼0,02), el tamañ o (o5 mm, OR ¼3,37; po0,001) y la medicació n administrada (combinació n de alfabloqueantes y AINE, OR ¼8,70; po0,001) resultaron factores predictivos para la expulsió n. El aná lisis multivariante confirmó al tamañ o (p ¼0,006) y a la medicació n (po0,001) como factores predictivos independientes. El tratamiento con una combinació n de AINE y alfabloqueantes multiplica por 8,21 (intervalo de confianza del 95%: 3,37-20,01) las posibilidades de expulsió n en comparació n con la mera actitud expectante.Conclusiones: El tamañ o del cá lculo y la medicació n son factores predictivos independientes para la expulsió n de la litiasis ureteral.

show abstract

Oral Diclofenac in the Prophylactic Treatment of Recurrent Renal Colic

Cited by 77 publications

References 5 publications

Pediatric primary urolithiasis: Symptoms, medical management and prevention strategies

Pediatric primary urolithiasis: Symptoms, medical management and prevention strategies

Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost-effectiveness analysis of a calcium channel blocker (nifedipine) and an alpha-blocker (tamsulosin) (the SUSPEND trial)

Factores predictivos para la expulsión de la litiasis ureteral

Contact Info

Product

Resources

About